BeStock  
Stocks › Biotechnology › ORIC

Oric Pharmaceuticals ORIC

US equityMarket cap rank #3332Biotechnology
$7.36 −$0.34 (-4.42%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.37 +0.14%
Open$7.58
Prev close$7.70
Day range$7.28 – $8.00
Volume1.46M
Market cap$764.94M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$45.30M-16.0% YoY
Net profit-$41.49M-14.1% YoY
Diluted EPS-$0.38+19.1% YoY
Free cash flow-$31.96M-3.4% YoY
Operating cash flow-$31.61M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-34.6MSep '24$-36.3MDec '24$-30.0MMar '25$-36.4MJun '25$-32.6MSep '25$-30.5MDec '25$-35.8MMar '26$-41.5MJun '26

Diluted EPS by quarter

-0.49Sep '24-0.51Dec '24-0.42Mar '25-0.47Jun '25-0.33Sep '25-0.30Dec '25-0.34Mar '26-0.38Jun '26

Free cash flow by quarter

$-29.2MSep '24$-28.3MDec '24$-32.9MMar '25$-30.9MJun '25$-25.1MSep '25$-22.7MDec '25$-32.4MMar '26$-32.0MJun '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-39.8%
Return on assets-37.4%
Return on invested capital-39.4%
Current ratio13.19
Liabilities / assets5.8%
Cash & investments$264.76M
Net cash (debt)$264.76M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $45.30M $39.62M $143.00M $34.55M $36.67M
Selling and Admin Expenses $9.00M $8.18M $33.19M $8.70M $7.90M
-General & Admin Expense $9.00M $8.18M $33.19M $8.70M $7.90M
Research & Development $36.30M $31.44M $109.82M $25.86M $28.77M
Operating Profit -$45.30M -$39.62M -$143.00M -$34.55M -$36.67M
Other Income (Expense) $3.80M $3.85M $13.54M $4.05M $4.08M
Other Non-Operating Income (Expenses) $3.80M $3.85M $13.54M $4.05M $4.08M
Pretax Profit -$41.49M -$35.77M -$129.47M -$30.51M -$32.59M
Net Profit -$41.49M -$35.77M -$129.47M -$30.51M -$32.59M
Profit from Continuing Operations -$41.49M -$35.77M -$129.47M -$30.51M -$32.59M
Net Income to Parent Company -$41.49M -$35.77M -$129.47M -$30.51M -$32.59M
Net Income to Common Stockholders -$41.49M -$35.77M -$129.47M -$30.51M -$32.59M
Basic EPS -$0.38 -$0.34 -$1.47 -$0.30 -$0.33
Diluted EPS -$0.38 -$0.34 -$1.47 -$0.30 -$0.33

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $404.69M $436.76M $408.89M $408.89M $431.19M
Total Current Assets $273.70M $290.23M $288.47M $288.47M $295.59M
Cash and Cash Equivalents & Short-Term Investments $264.76M $281.93M $281.49M $281.49M $287.14M
-Cash and Cash Equivalents $37.48M $56.40M $45.67M $45.67M $49.67M
-Short Term Investments $227.28M $225.54M $235.82M $235.82M $237.47M
Other Current Assets $8.93M $8.30M $6.98M $6.98M $8.45M
Total Non-Current Assets $130.99M $146.53M $120.42M $120.42M $135.60M
Net PPE $2.24M $2.15M $2.42M $2.42M $2.56M
-Gross PPE $10.43M $10.07M $10.07M $10.07M $10.72M
-Accumulated Depreciation -$8.19M -$7.92M -$7.65M -$7.65M -$8.16M
Investments and Advances $122.80M $137.78M $110.76M $110.76M $125.91M
-Available for Sale Securities $122.80M $137.78M $110.76M $110.76M $125.91M
Other Non-Current Assets $5.95M $6.60M $7.25M $7.25M $7.13M
Total Liabilities $23.43M $21.21M $24.53M $24.53M $24.27M
Total Current Liabilities $20.76M $17.77M $20.42M $20.42M $20.18M
Payables $3.87M $2.90M $3.82M $3.82M $2.90M
-Accounts Payable $3.87M $2.90M $3.82M $3.82M $2.90M
Current Accrued Expenses $8.44M $7.78M $5.17M $5.17M $7.11M
Short-Term Debt and Capital Lease Obligation $3.33M $3.30M $3.33M $3.33M $3.30M
-Current Capital Lease Obligation $3.33M $3.30M $3.33M $3.33M $3.30M
Total Non-Current Liabilities $2.67M $3.43M $4.11M $4.11M $4.09M
Other Non-Current Liabilities $2.67M $3.43M $4.11M $4.11M $4.09M
Total Equity $381.26M $415.56M $384.36M $384.36M $406.92M
Stockholders' Equity $381.26M $415.56M $384.36M $384.36M $406.92M
Capital Stock $11,000.00 $11,000.00 $11,000.00 $11,000.00 $11,000.00
-Common Stock $11,000.00 $11,000.00 $11,000.00 $11,000.00 $11,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.15B $1.14B $1.08B $1.08B $1.07B
Retained Earnings -$769.50M -$728.01M -$692.24M -$692.24M -$661.74M
Gains/Losses Not Affecting Retained Earnings -$1.02M -$290,000.00 $786,000.00 $786,000.00 $615,000.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$31.61M -$32.44M -$110.97M -$22.48M -$25.11M
Net cash flow from continuing operations -$31.61M -$32.44M -$110.97M -$22.48M -$25.11M
Net Income from Continuing Operations -$41.49M -$35.77M -$129.47M -$30.51M -$32.59M
Depreciation & Depletion & Amortization $264,000.00 $270,000.00 $1.22M $320,000.00 $288,000.00
Change in Working Capital $2.24M -$4.00M -$5.46M $1.66M $2.14M
-Change in Prepaid Assets $21,000.00 -$679,000.00 $1.79M $2.11M $782,000.00
-Change in Payables and Accrued Expense $2.22M -$3.32M -$7.25M -$448,000.00 $1.36M
Net cash flow from investing $11.86M -$17.98M -$148.03M $16.98M -$110.54M
Net Cash Flow from Continuing Investing Activities $11.86M -$17.98M -$148.03M $16.98M -$110.54M
Net PPE Purchase and Sale -$356,000.00 -$2,000.00 -$712,000.00 -$227,000.00 -$35,000.00
Net Investment Purchase and Sale $12.22M -$17.97M -$147.32M $17.21M -$110.50M
Financing Cash Flow $828,000.00 $61.14M $245.26M $1.50M $109.45M
Net Cash Flow from Continuing Financing Activities $828,000.00 $61.14M $245.26M $1.50M $109.45M
Net Common Stock Issuance $0.00 $60.88M $244.37M $0.00 $110.44M
Proceeds from Stock Option Exercised $828,000.00 $1.25M $3.29M $1.50M $748,000.00
Net Other Financing Charges $0.00 -$993,000.00 -$2.40M $0.00 -$1.74M
Ending Cash Balance $37.97M $56.89M $46.16M $46.16M $50.16M
Net Change in Cash -$18.91M $10.73M -$13.74M -$4.00M -$26.20M
Beginning Cash Balance $56.89M $46.16M $59.90M $50.16M $76.36M
Free Cash Flow -$31.96M -$32.44M -$111.68M -$22.71M -$25.15M

Discussion

No comments yet — be the first to weigh in on ORIC.

Sign in to join the discussion.

Scroll to Top